Hemostemix Inc. announced the Journal of Biomedical Research and Environmental Sciences published the Company's Phase II randomized clinical trial results. The publication highlights the results of no option critical limb ischemia patients who started the clinical trial with an ulcer, comparing wound healing, amputation, and mortality between the patients treated with ACP- 01 and patients treated with a placebo, and stated the following: 67 patients with no option Critical limb ischemia were allocated to treatment with ACP-01 (46/67) or placebo (21/67). From this data, only patients who presented with wound ulcers before administration of ACP-01 were reviewed (21 treatment, 8 placebo).

Ulcer size in the treated group decreased from a mean of 1.46 cm2 to 0.48 mm2 (p = 0.01) by 3 months. There was no significant decrease in the size of the ulcers of the placebo group (p < 0.54). At one year there were no complications related to treatment.

The treatment group had one amputation (4.8%) and one death (4.8%). The placebo group had 2 amputations (25%) and 1 death (12.5%).